Policymakers and organizations should focus more on developing alternative payment models to broaden access to drugs without risking the funds necessary to fuel drug development, Forward Ventures Founding Managing Member Standish Fleming writes in a recent article on Forbes.
“Drug development is already on the verge of losing money; to drive it into the red risks collapse,” he writes. “… The problem is that people have difficulty paying for medicine. Mandating lower prices would put the supply at risk.”
Fleming writes that “we should do everything we can to incentivize” drug development.
To read the full article on Forbes, click here.